REG - OptiBiotix Health - Grant of Options

OptiBiotix HealthAnnouncement

27/03/2019 15:20

RNS Number : 2216U
OptiBiotix Health PLC
27 March 2019
 


OPTIBIOTIX HEALTH PLC (the "Company")
Grant of Options
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the grant of options to Frederic Narbel, a newly appointed Director of the Company, at an exercise price of 78.5p. Full details of the options agreement are set out below.
 




Director


Number of options


Exercise price




Frederic Narbel


500,000


78.5p




 
The options were granted with an effective date of 25 March 2019 and may be exercised up to 10 years from this date.
 
The options have performance criteria attached to them which includes significant revenue targets. Option holders can only purchase and/or sell shares once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
Stephen O'Hara, CEO of OptiBiotix, commented: "The ability to attract and retain key staff who deliver to revenue targets and build shareholder value is important to OptiBiotix's continued success.  The granting of share options helps OptiBiotix compete with the remuneration packages offered by larger corporates and incentivises the team to focus both effort and activity on rapidly growing revenues and building shareholder value. These options are offered to staff and do not become exercisable (i.e. sellable) until they achieve significant revenue targets which, if achieved, will create substantive shareholder value".
 
For further information, please contact:




 
OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below




 


 




Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner / Ludovico Lazzaretti


 




 
finnCap (Broker)


 
Tel: 020 7220 0500




Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)


 




Camille Gochez (Corporate Broking)


 




 


 




Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001




 


 



 
 
 



 
 
 
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 
 
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 
 
 




Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014




1


Details of the person discharging managerial responsibilities/person closely associated




a.


Name


Frederic Narbel




2


Reason for notification


 




a.


Position/Status


Managing Director of Prebiotics, Director of the Company




b.


Initial notification/
Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a.


Name


OptiBiotix Health Plc




b.


LEI


213800UKYQFT941QHS14




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a.


Description of the financial instrument, type of instrument



Identification Code




Options over 500,000 ordinary shares of 2p each with an exercise price of 78.5p

 
 
ISIN: GB00BP0RTP38




b.


Nature of the transaction


 Award of option to purchase ordinary shares of the Company. Following the transaction, Mr Frederic Narbel has an interest in options over 500,000 ordinary shares.




c.


Price(s) and volume(s)


 


 


 


 


 




 


Price(s) per share


Volume(s)


 




78.5p


500,000


 




 
 




d.


Date of the transaction


27 March 2019




e.


Place of the transaction


London Stock Exchange, AIM




 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHLLFLEVSIDFIA